Increased myeloperoxidase plasma levels in rheumatoid arthritis

High myeloperoxidase (MPO) serum levels have been shown in several inflammatory diseases, including rheumatoid arthritis (RA). However, the correlation between MPO levels and disease activity in RA patients is still controversial. The aim of the study was to determine MPO plasma levels in RA patients and to investigate potential correlations between MPO levels and disease activity and treatment. MPO plasma levels were measured by ELISA according the manufacturer’s instructions. Disease activity was measured by DAS28 ESR and DAS28 CRP scores, and patients were classified into 4 groups: group 1 DAS28?<?2.6; group 2: 2.6?≤?DAS28?≤?3.2; group 3: 3.2?<?DAS28?≤?5.1 and group 4: DAS28?>?5.1. Rheumatoid factor (RF) was measured by latex agglutination test, and anti-cyclic citrullinated peptide (anti-CCP) antibodies were detected by ELISA with a commercial kit. Fifty-seven female RA patients (mean age: 46.02?±?13.47?years, mean disease duration: 115.77?±?99.44?months) and sixty gender- and age-paired healthy controls were included. Mean MPO plasma levels were significantly higher in patients than in controls (72.27?pM vs. 40.78?pM, P?=?0.007). RF was found in 59.6% and anti-CCP in 80.7% of the RA patients. No significant difference in MPO levels was seen among the four RA disease activity groups. We did not find significant correlation between MPO levels and disease activity as measured by DAS28 score. In conclusion, we observed significantly higher MPO plasma levels in RA patients when compared to healthy controls. However, we did not find correlation between MPO plasma level and disease activity.